Paratek Pharma buy Quitte
Start price
02.03.17
/
50%
€14.25
Target price
10.04.17
€20.20
Performance (%)
43.35%
End price
10.04.17
€20.43
Summary
This prediction ended on 10.04.17 with a price of €20.43. With a performance of 43.35% the BUY prediction by Quitte was a big success. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Paratek Pharma | - | - | - | - |
| iShares Core DAX® | -0.197% | -1.724% | 12.342% | 55.750% |
| iShares Nasdaq 100 | -3.612% | -3.768% | 0.437% | 80.820% |
| iShares Nikkei 225® | 1.176% | 2.165% | 19.971% | 49.596% |
| iShares S&P 500 | -0.825% | -1.916% | 0.099% | 55.940% |
Comments by Quitte for this prediction
In the thread Paratek Pharma diskutieren
sieht doch gut aus
Stand 2. März 2017
BOSTON (AP) _ Paratek Pharmaceuticals Inc. (PRTK) on Thursday reported a loss of $26.5 million in its fourth quarter.
The Boston-based company said it had a loss of $1.16 per share.
The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.29 per share.
The pharmaceutical company posted revenue of $29,000 in the period.
For the year, the company reported that its loss widened to $111.6 million, or $5.51 per share. Revenue was reported as $29,000.
Paratek shares have decreased roughly 2 percent since the beginning of the year. The stock has dropped nearly 3 percent in the last 12 months.